UroGen Pharma appoints Christopher Degnan as CFO; Don Kim resigns effectively Oct 8, 2024

UroGen Pharma Ltd.

Don Kim resigned as CFO, principal financial and accounting officer effective Oct 8, 2024; will provide part-time consulting through Apr 28, 2025 for $36,260.
Kim receives 9 months base salary continuation, $217,590 lump sum (2024 target bonus), and COBRA reimbursement for 9 months.
Christopher Degnan appointed CFO effective Oct 8; prior CFO of Galera Therapeutics and Verrica Pharmaceuticals.
Degnan receives $500,000 annual base salary, 50% target bonus, and inducement equity: option for 74,142 shares at $13.11 and 13,450 RSUs vesting over 3 years.
Severance terms for Degnan include 6 months base salary, pro-rata bonus, and accelerated vesting of 8.33% of equity on qualifying termination.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Don Kim

Chief Financial Officer

URGN · UroGen Pharma Ltd.

Effective: 2024-10-08
Successor: Christopher Degnan
Filed: October 9, 2024, 7:59 PM ET

pursuant to which Mr. Kim resigned from his positions as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective October 8, 2024

Appointed

Christopher Degnan

Chief Financial Officer

URGN · UroGen Pharma Ltd.

Effective: 2024-10-08
Filed: October 9, 2024, 7:59 PM ET

the Company appointed Christopher Degnan as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Don Kim resigned as Chief Financial Officer at UroGen Pharma Ltd..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

pursuant to which Mr. Kim resigned from his positions as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective October 8, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher Degnan was appointed as Chief Financial Officer at UroGen Pharma Ltd..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

the Company appointed Christopher Degnan as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.

View on SEC.gov

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-24-234808

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.